Annual SGA
$178.18 M
+$67.36 M+60.78%
December 31, 2024
Summary
- As of March 12, 2025, RXRX annual SGA is $178.18 million, with the most recent change of +$67.36 million (+60.78%) on December 31, 2024.
- During the last 3 years, RXRX annual SGA has risen by +$120.50 million (+208.91%).
- RXRX annual SGA is now at all-time high.
Performance
RXRX SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$77.19 M
+$39.43 M+104.43%
December 31, 2024
Summary
- As of March 12, 2025, RXRX quarterly SGA is $77.19 million, with the most recent change of +$39.43 million (+104.43%) on December 31, 2024.
- Over the past year, RXRX quarterly SGA has increased by +$39.43 million (+104.43%).
- RXRX quarterly SGA is now at all-time high.
Performance
RXRX Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$4.90 B
-$463.66 M-10.45%
December 31, 2024
Summary
- As of March 12, 2025, RXRX TTM SGA is -$4.90 billion, with the most recent change of -$463.66 million (-10.45%) on December 31, 2024.
- Over the past year, RXRX TTM SGA has dropped by -$5.03 billion (-3826.87%).
- RXRX TTM SGA is now -2193.62% below its all-time high of -$213.60 million.
Performance
RXRX TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
RXRX Selling, General & Administrative Expenses Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +60.8% | +104.4% | -3826.9% |
3 y3 years | +208.9% | +104.4% | -3826.9% |
5 y5 years | +840.2% | +104.4% | -3826.9% |
RXRX Selling, General & Administrative Expenses Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | at high | +208.9% | at high | +302.0% | -286.6% | at low |
5 y | 5-year | at high | +840.2% | at high | +1396.1% | -2193.6% | at low |
alltime | all time | at high | +840.2% | at high | +1396.1% | -2193.6% | at low |
Recursion Pharmaceuticals Selling, General & Administrative Expenses History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | $178.18 M(+60.8%) | $77.19 M(+104.4%) | $178.18 M(+35.5%) |
Sep 2024 | - | $37.76 M(+18.6%) | $131.46 M(+7.0%) |
Jun 2024 | - | $31.83 M(+1.4%) | $122.90 M(+3.0%) |
Mar 2024 | - | $31.41 M(+3.1%) | $119.36 M(+7.7%) |
Dec 2023 | $110.82 M(+35.8%) | $30.46 M(+4.3%) | $110.82 M(+10.6%) |
Sep 2023 | - | $29.20 M(+3.2%) | $100.20 M(+10.7%) |
Jun 2023 | - | $28.29 M(+23.7%) | $90.49 M(+8.5%) |
Mar 2023 | - | $22.87 M(+15.3%) | $83.40 M(+2.2%) |
Dec 2022 | $81.60 M | $19.84 M(+1.8%) | $81.60 M(+0.8%) |
Sep 2022 | - | $19.49 M(-8.1%) | $80.96 M(+4.9%) |
Jun 2022 | - | $21.20 M(+0.6%) | $77.16 M(+10.5%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2022 | - | $21.07 M(+9.8%) | $69.82 M(+21.0%) |
Dec 2021 | $57.68 M(+128.4%) | $19.20 M(+22.4%) | $57.68 M(+25.2%) |
Sep 2021 | - | $15.69 M(+13.3%) | $46.05 M(+23.4%) |
Jun 2021 | - | $13.85 M(+55.0%) | $37.33 M(+30.4%) |
Mar 2021 | - | $8.94 M(+18.0%) | $28.63 M(+13.4%) |
Dec 2020 | $25.26 M(+33.3%) | - | - |
Dec 2020 | - | $7.57 M(+8.8%) | $25.26 M(+42.8%) |
Sep 2020 | - | $6.96 M(+35.0%) | $17.68 M(+65.0%) |
Jun 2020 | - | $5.16 M(-7.2%) | $10.72 M(+92.8%) |
Mar 2020 | - | $5.56 M | $5.56 M |
Dec 2019 | $18.95 M | - | - |
FAQ
- What is Recursion Pharmaceuticals annual SGA?
- What is the all time high annual SGA for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual SGA year-on-year change?
- What is Recursion Pharmaceuticals quarterly SGA?
- What is the all time high quarterly SGA for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly SGA year-on-year change?
- What is Recursion Pharmaceuticals TTM SGA?
- What is the all time high TTM SGA for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals TTM SGA year-on-year change?
What is Recursion Pharmaceuticals annual SGA?
The current annual SGA of RXRX is $178.18 M
What is the all time high annual SGA for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual SGA is $178.18 M
What is Recursion Pharmaceuticals annual SGA year-on-year change?
Over the past year, RXRX annual SGA has changed by +$67.36 M (+60.78%)
What is Recursion Pharmaceuticals quarterly SGA?
The current quarterly SGA of RXRX is $77.19 M
What is the all time high quarterly SGA for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly SGA is $77.19 M
What is Recursion Pharmaceuticals quarterly SGA year-on-year change?
Over the past year, RXRX quarterly SGA has changed by +$39.43 M (+104.43%)
What is Recursion Pharmaceuticals TTM SGA?
The current TTM SGA of RXRX is -$4.90 B
What is the all time high TTM SGA for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high TTM SGA is -$213.60 M
What is Recursion Pharmaceuticals TTM SGA year-on-year change?
Over the past year, RXRX TTM SGA has changed by -$5.03 B (-3826.87%)